Lineage Cell Therapeutics, Inc. (LCTX)
XASE:LCTX
Want to see LCTX full AI Analyst Report?
LCTX Stock Chart & Stats
$1.71
-$0.04(-6.64%)
At close: 4:00 PM EST
$1.71
-$0.04(-6.64%)
Day’s Range― - ―
52-Week Range$0.85 - $2.09
Previous CloseN/A
Volume522.43K
Average Volume (3M)1.24M
Market Cap
$314.12M
Enterprise Value$278.08M
Total Cash (Recent Filing)$53.38M
Total Debt (Recent Filing)$2.39M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Aug 06, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding249,298,300
10 Day Avg. Volume1,277,482
30 Day Avg. Volume1,241,041
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)8.63
Price to Sales (P/S)26.40
P/FCF Ratio-19.77
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue18.82
Enterprise Value/Gross Profit19.20
Enterprise Value/Ebitda-6.45
Forecast
1Y Price Target
$6.25Price Target Upside265.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.07
Revenue Forecast (FY)$15.63M
Bulls Say, Bears Say
Bulls Say
Scalable AlloSCOPE Manufacturing PlatformLineage has demonstrated reproducible two-tier banking and an FDA-cleared final product, with mathematical potential to produce millions of vials. That durable manufacturing scaling lowers per-dose cost and supports an off-the-shelf allogeneic model, improving commercialization feasibility and margin leverage as volumes rise.
Partner Validation For OpRegen (Roche/Genentech)Long‑term durability data and Roche/Genentech expanding GAlette to 17 sites materially de‑risks OpRegen development. Sustained partner investment provides operational scale, external development funding and potential milestone/royalty economics, strengthening commercial pathway and lowering Lineage's solo execution burden.
Multi-year Cash Runway Plus Contingent FundingReported cash of $53.4M, potential ~$32M in warrants and eligibility for up to $615M in partner milestones create a multi‑year funding backdrop. Combined with disciplined spend guidance (~$30M/yr), this mix extends runway into 2028 and reduces immediate financing pressure while enabling continued R&D and scale-up execution.
Bears Say
Persistent Cash Burn And Negative Operating Cash FlowOperating and free cash flows are materially negative on a trailing‑twelve‑month basis (about -$22M), reflecting ongoing R&D and scale-up spend. While free cash flow improved vs prior periods, the company remains reliant on external funding, milestone receipts or equity raises to sustain multi‑stage development and commercial scale.
Partner Dependence And Timing Uncertainty For OpRegenProgress and public timing for OpRegen are controlled largely by Roche/Genentech decisions and GAlette disclosures. This structural dependence creates uncertainty around milestone realization, trial expansion timing and partner‑driven cash flows, potentially delaying revenue inflection points and diluting Lineage's near‑term strategic control.
Islet Program Scale And Technical ComplexityThe islet (T1D) program faces enduring manufacturing hurdles: required doses near ~1 billion cells per patient and commercial production likely needs ~80L reactor scale. Uncertain AlloSCOPE upper limits and differentiation heterogeneity raise execution, cost and timing risks that can materially extend development timelines and capital needs.
Lineage Therap News
LCTX FAQ
What was Lineage Cell Therapeutics, Inc.’s price range in the past 12 months?
Lineage Cell Therapeutics, Inc. lowest stock price was $0.85 and its highest was $2.09 in the past 12 months.
What is Lineage Cell Therapeutics, Inc.’s market cap?
Lineage Cell Therapeutics, Inc.’s market cap is $314.12M.
When is Lineage Cell Therapeutics, Inc.’s upcoming earnings report date?
Lineage Cell Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 44 days.
How were Lineage Cell Therapeutics, Inc.’s earnings last quarter?
Lineage Cell Therapeutics, Inc. released its earnings results on May 12, 2026. The company reported -$0.03 earnings per share for the quarter, missing the consensus estimate of -$0.02 by -$0.01.
Is Lineage Cell Therapeutics, Inc. overvalued?
According to Wall Street analysts Lineage Cell Therapeutics, Inc.’s price is currently Undervalued.
Does Lineage Cell Therapeutics, Inc. pay dividends?
Lineage Cell Therapeutics, Inc. does not currently pay dividends.
What is Lineage Cell Therapeutics, Inc.’s EPS estimate?
Lineage Cell Therapeutics, Inc.’s EPS estimate is -0.02.
How many shares outstanding does Lineage Cell Therapeutics, Inc. have?
Lineage Cell Therapeutics, Inc. has 249,298,300 shares outstanding.
What happened to Lineage Cell Therapeutics, Inc.’s price movement after its last earnings report?
Lineage Cell Therapeutics, Inc. reported an EPS of -$0.03 in its last earnings report, missing expectations of -$0.02. Following the earnings report the stock price went down -3.759%.
Which hedge fund is a major shareholder of Lineage Cell Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LCTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lineage Therap Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.25 (265.50% Upside)
$6.25 (265.50% Upside)
Blogger Sentiment
Bullish
LCTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 6.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 2.0%
Last 30 Days ▲ 2.9%
Last 30 Days ▲ 2.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
32.24%
12-Months-Change
Fundamentals
Return on Equity
-152.10%
Trailing 12-Months
Asset Growth
-1.99%
Trailing 12-Months
Company Description
Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. (LCTX) operates as a biotechnology firm in the clinical trial phase, dedicated to pioneering innovative cell-based treatments for various degenerative conditions across the United States and globally. The company's pipeline features several key therapeutic candidates: OpRegen, a replacement therapy utilizing retinal pigment epithelium cells, is currently undergoing Phase I/IIa clinical trials to address dry age-related macular degeneration. OPC1, an oligodendrocyte progenitor cell therapy, is being evaluated in Phase I/IIa multicenter clinical studies for individuals suffering from acute spinal cord injuries. VAC2, an allogeneic cancer immunotherapy employing antigen-presenting dendritic cells, has advanced to Phase I clinical trials for the treatment of non-small cell lung cancer. Beyond its development pipeline, Lineage Cell Therapeutics also markets Renevia, a product designed for facial aesthetics. The company's research and development endeavors extend to exploring therapeutic solutions for a broader range of retinal and neurological disorders, as well as additional oncology indications. A strategic alliance exists between Lineage Cell Therapeutics, Inc. and Orbit Biomedical, Ltd. The organization, which was established in 1990 and is headquartered in Carlsbad, California, previously operated under the name BioTime, Inc. before rebranding in August 2019.
LCTX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial scientific and operational progress across Lineage's manufacturing platform and pipeline: AlloSCOPE advances, the launch and initial preclinical success of COR1, ILT1 scale-up milestones, completed engineering runs for ReSonance, device performance and site expansion for OPC1, SAB and clinical leadership hires, and partner validation for OpRegen (including multi-year vision durability and expansion to 17 sites). Financials show modest revenue, rising R&D and operating expenses, and a larger net loss year-over-year, but a cash runway into 2028 plus potential warrant proceeds and sizeable contingent Roche/Genentech milestones mitigate near-term funding concerns. Program risks remain — notably islet scale-up technical challenges, timing uncertainty tied to partners (OpRegen), and some earlier-stage setbacks (photoreceptor IP change, CIRM non-award) — however the volume and quality of operational and scientific milestones reported suggest progress materially outweighs current financial and program risks.View all LCTX earnings summariesLCTX Stock 12 Month Forecast
Average Price Target
$6.25
▲(265.50% Upside)
Technical Analysis
Amarin
―
Tvardi Therapeutics
―
DBV Technologies SA - American
―
4D Molecular Therapeutics
―
Aura Biosciences Inc
―
Ownership Overview
13.98% Insiders
4.52% Mutual Funds
27.10% Other Institutional Investors
50.47% Public Companies and
Individual Investors